COMMUNIQUÉS West-GlobeNewswire

Emergent BioSolutions Reports First Quarter 2025 Financial Results
07/05/2025
First Quarter 2025 Total Revenues of $222.2 million, decrease of 26% versus prior year First Quarter 2025 Net Income of $68.0 million, increase of 656% versus prior year First Quarter 2025 Gross Margin % of 50% and [...]
electroCore Announces First Quarter 2025 Financial Results
07/05/2025
First quarter 2025 net sales of $6.7 million, an increase of 23% over first quarter 2024 Closed the acquisition of NeuroMetrix, Inc. (“NeuroMetrix”); first quarter 2025 unaudited Quell net sales of approximately $170, [...]
InnovAge Earns Recertification as a Great Place to Work
07/05/2025
Employee feedback highlights pride in and commitment to serving the community DENVER, May 07, 2025 (GLOBE NEWSWIRE) -- InnovAge, a leading provider of Program of All-Inclusive Care for the Elderly (PACE) services, is [...]
Tenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
07/05/2025
Interim Data from Low Dose Cohort in MyPEAK TM -1 Clinical Trial of TN-201 Showed Encouraging Safety Profile, Transduction and Expression, Plus Improvements in Hypertrophy and NYHA Classification RIDGE Natural History [...]
Exagen Inc. Announces Proposed Public Offering of Common Stock
07/05/2025
CARLSBAD, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has commenced an underwritten public offering of shares of its [...]
Generation Bio Reports Recent Business Highlights and First Quarter 2025 Financial Results
07/05/2025
- Company continues to advance its strategy to develop first-in-class treatments for T cell-driven autoimmune diseases using its cell-targeted lipid nanoparticle (ctLNP) technology to deliver siRNA - Lead target and [...]
Inotiv Reports Second Quarter Financial Results for Fiscal 2025 and Provides Business Update
07/05/2025
— Second quarter fiscal 2025 revenue increased 4.4% to $124.3 million — Year-to-date fiscal 2025 revenue declined 4.1% to $244.2 million — Conference call scheduled for today at 4:30 pm ET WEST LAFAYETTE, Ind., May 07, [...]
OrthoPediatrics Corp. Reports First Quarter 2025 Financial Results and Increases Full Year 2025 Revenue Guidance
07/05/2025
First Quarter 2025 Revenue Increased 17% Year-over-Year WARSAW, Ind., May 07, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on [...]
OraSure Announces First Quarter 2025 Financial Results
07/05/2025
BETHLEHEM, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for [...]
MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance
07/05/2025
ROCKVILLE, Md., May 07, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and [...]
RxSight, Inc. Reports First Quarter 2025 Financial Results
07/05/2025
ALISO VIEJO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, [...]
Aardvark Therapeutics to Present at Upcoming Investor Conferences in May
07/05/2025
SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate [...]
LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
07/05/2025
New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 Cash, cash equivalents and marketable securities of $194.1 million as of March 31, 2025 Upwardly [...]
Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference
07/05/2025
SOUTH SAN FRANCISCO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked [...]
ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update
07/05/2025
1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue ( 1 ) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA ( 2 ) of $47.9 Million, [...]
MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance
07/05/2025
ROCKVILLE, MD, May 7, 2025 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of [...]
Context Therapeutics Reports First Quarter 2025 Operating and Financial Results
07/05/2025
CTIM-76 and CT-95 in Phase 1 Clinical Trials Cash and cash equivalents of $89.4 million as of March 31, 2025 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, May 07 [...]
Oncocyte to Release First Quarter 2025 Results on May 12, 2025
07/05/2025
IRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that it will report first quarter 2025 financial results after the market closes [...]
GENFIT : Assemblée Générale Mixte du 17 juin 2025 — modalités de mise à disposition des documents préparatoires
07/05/2025
Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 7 mai 2025 – GENFIT (Nasdaq et Euronext : GNFT) , société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de [...]

Pages